Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema SANTA CLARA, Calif. , January 16, 2020 Agilent Technologies Inc. (NYSE: A) is collaborating with researchers at two UK universities who are looking into the risk factors for atopic eczema (also known as atopic dermatitis), a chronic skin condition that affects one in five children... Read more

PerkinElmer Launches First FDA-Approved Assay Kit to Screen for Duchenne Muscular Dystrophy in Newborns

Available on PerkinElmer’s automated GSP® instrument, kit supports early diagnosis by measuring CK-MM concentration instead of CK enzyme activity WALTHAM, Mass.–(BUSINESS WIRE)–Dec. 13, 2019– PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that its GSP® Neonatal Creatine Kinase –MM (CK-MM) kit has received U.S. Food & Drug... Read more

Thermo Fisher Scientific to Bring One-Day Genomic Profiling to Hematology Oncology

Thermo Fisher Scientific to Bring One-Day Genomic Profiling to Hematology Oncology Comprehensive myeloid assay available in 2020 to run on the Ion Torrent Genexus System CARLSBAD, Calif., Dec. 5, 2019 /PRNewswire/ — Clinical researchers who take a traditional sequential approach to analyze myeloid malignancies, a highly heterogeneous group of disorders, face a major hurdle: a... Read more

QIAGEN and DiaSorin receive FDA approval for the LIAISON QuantiFERON-TB Gold Plus Test on LIAISON platforms and begin commercial launch

Germantown, Maryland; Hilden, Germany; and Saluggia, Italy, November 27, 2019 –QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the U.S. launch of an automated workflow for QuantiFERON-TB Plus (QFT-Plus), the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on DiaSorin’s LIAISON platforms. The U.S. Food and Drug Administration... Read more

Danaher Will Commence Exchange Offer Related To Divestiture Of Its Remaining Interest In Envista Through A Split-Off

Danaher Will Commence Exchange Offer Related To Divestiture Of Its Remaining Interest In Envista Through A Split-Off WASHINGTON, Nov. 15, 2019 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced today that it will commence an exchange offer related to the split-off of its remaining interest in Envista Holdings Corporation (NYSE: NVST). Envista completed its initial public offering... Read more

World’s First Cyclic IMS Mass Spectrometer Installed at Aston University

Technology brings university scientists unparalleled potential for chemical, biological and human disease research First commercial research instrument of its kind in the world. MILFORD, Mass.–(BUSINESS WIRE)–Nov. 7, 2019– Aston University and Waters Corporation (NYSE: WAT) announced today the completed installation of the world’s first Waters™ SELECT SERIES™ Cyclic™ IMS (ion mobility spectrometry) mass spectrometer within the University’s School of Health and Life... Read more